Expert group publishes new T.I.M.E. clinical decision support tool to help improve the consistency of daily wound care practice

14 March 2019

Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, today welcomes the publication of an expert working group recommendation targeting consistency in clinical practice and improved outcomes through an evolved T.I.M.E. framework.¹

The T.I.M.E. framework was originally developed by an international group of wound healing experts to provide a structured approach to wound bed preparation.^2,3 This tool has previously tended to focus mainly on the wound rather than on the patient and their wider health issues.⁴ Smith & Nephew brought together leading wound expert practitioners, building on the original framework, to develop a new T.I.M.E. clinical decision support tool (CDST). T.I.M.E. CDST takes the healthcare professional through a simple five step approach consisting of a) a holistic, multidisciplinary assessment, b) use of the multidisciplinary team, c) control of systemic disorders, d) the decision on the treatment plan and e) an evaluation of outcomes.

“We welcome the development and introduction of T.I.M.E. CDST”, said Paolo Di Vincenzo, Senior Vice President Global Marketing, Smith & Nephew Wound Management “as it is designed by experts to help provide an easy to adopt structure for every day practitioners to manage wound care more effectively. We believe the correct implementation of T.I.M.E. CDST will help practitioners better assess what’s needed for each patient, when to use what product, and for how long. With a complete leading portfolio that can help address every aspect of T.I.M.E. supporting the broad range of clinical needs our customers face daily, we look forward to supporting the T.I.M.E. CDST implementation in routine clinical practice, to help reduce practice variation, improve healing rates and resource utilization”.

“Despite the understanding that wounds are a common problem affecting the individual, the health service and society as a whole, there continues to be a lack of a systematic, structured evidence-based approach to wound management.” said Zena Moore, Professor of Nursing and Head of the School of Nursing & Midwifery and Director of the Skin Wounds and Trauma Research Centre, Royal College of Surgeons, Ireland. “In answering this need, we developed the T.I.M.E. CDST tool. The next step in the journey is evaluation of the model, education of health professionals about the tool, implementation and evaluation of outcomes achieved from its use. It is evident that exciting times lie ahead.”

To learn more about the T.I.M.E. CDST please visit http://www.smith-nephew.com/time/

Enquiries

Media

Dave Snyder
+1 (978) 749-1440
Smith & Nephew

About Smith & Nephew

Smith & Nephew is a portfolio medical technology business with leadership positions in Orthopaedics, Advanced Wound Management and Sports Medicine. Smith & Nephew has more than 16,000 employees and a presence in more than 100 countries. Annual sales in 2018 were $4.9 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on Twitter, LinkedIn or Facebook.

To learn more about how we can help you get CLOSER TO ZERO™ delay in wound healing, please visit www.closertozero.com

_{Forward-looking Statements}

_{This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.}

_{◊ Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.}